about
Smac mimetic bypasses apoptosis resistance in FADD- or caspase-8-deficient cells by priming for tumor necrosis factor α-induced necroptosisRIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosisAn advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imagingLoss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.Efficient RNA interference in patients' acute lymphoblastic leukemia cells amplified as xenografts in mice.NOXA as critical mediator for drug combinations in polychemotherapy.Effects of p38α/β inhibition on acute lymphoblastic leukemia proliferation and survival in vivoAnti-leukemic effects of the V-ATPase inhibitor Archazolid A.Activation of DNA damage response by antitumor therapy counteracts the activity of vinca alkaloids.The adaptor protein FADD and the initiator caspase-8 mediate activation of NF-κB by TRAIL.Cell cycle-arrested tumor cells exhibit increased sensitivity towards TRAIL-induced apoptosis.Important role of caspase-8 for chemosensitivity of ALL cells.Small molecule XIAP inhibitors sensitize childhood acute leukemia cells for CD95-induced apoptosis.Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects.CD95/Apo-1/Fas: independent cell death induced by doxorubicin in normal cultured cardiomyocytes.Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells.MycN and IFNgamma cooperate in apoptosis of human neuroblastoma cells.TRAIL-receptor costimulation inhibits proximal TCR signaling and suppresses human T cell activation and proliferation.TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB.TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo.Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics.The target landscape of clinical kinase drugs.Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations.Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.Leukemia-initiating cells of patient-derived acute lymphoblastic leukemia xenografts are sensitive toward TRAIL.Spatiotemporal patterning of EpCAM is important for murine embryonic endo- and mesodermal differentiation.Betulinic acid: a new cytotoxic agent against malignant brain-tumor cells.CRISPR/Cas9-edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC.Disruption of the PRKCD-FBXO25-HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis.Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistanceCombined inhibition of receptor tyrosine and p21-activated kinases as a therapeutic strategy in childhood ALLInvolvement of CD95/Apo1/Fas in Cell Death After Myocardial IschemiaTargeting the ER-mitochondria interface sensitizes leukemia cells towards cytostaticsCharacteristics and Therapeutic Targeting of Minimal Residual Disease in Childhood Acute Lymphoblastic LeukemiaSRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4Mitochondrial Thioredoxin Reductase Is Essential for Early Postischemic Myocardial ProtectionA rare subgroup of leukemia stem cells harbors relapse-inducing potential in acute lymphoblastic leukemiaThe Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
P50
Q24294685-829E82BA-1237-4929-B9D1-F23A63D73464Q24299986-C946578E-12D5-4EA7-B9D1-0961087BA950Q27311229-A5487F4E-F245-4268-BBA2-1E727C4A0226Q30313615-6E3FFC99-ABC4-4C25-AB7B-96E99102E9C0Q35950948-2520EA4F-05E3-40DF-A798-0303B443EFADQ36071973-C1621ABD-9951-4AA5-B1BB-AB777EF46C6DQ37726491-FBBA7218-E25B-46FC-8424-692C01449CDAQ38825585-150EC809-BBA6-45D2-B1B8-1E602A708DA0Q39044950-98D06074-F75E-4AB9-BF81-9F9D4B24D7B3Q39253903-19D60103-790F-4031-9C14-1FB444E392E5Q39406143-45214173-4DBF-4ACD-BE07-2DE15335549DQ39456086-371FA2B0-C54B-4724-8633-7BBCA5B472A8Q39813227-9BA9C256-7E58-4672-B228-1D94D23E4E6DQ40377782-9D584922-B3E2-4F95-B8A2-96B3F51BA3D6Q40459939-C711DAB5-876B-4DFB-B605-3FE13A380D37Q40516619-149890BF-81ED-4352-B72E-67BBB9E603CDQ41019633-A2AB7717-79BB-4BC5-BA96-28BD4FB2D5EFQ41740977-31611DDA-5AD6-4487-9F27-ECD625B89BE1Q44482351-9610E03B-CA39-4FE0-8EC9-93AAA537E29DQ45877501-1E55D86E-A048-409C-8DDB-6C1E679AFDE4Q47114899-8C503508-B87B-45B4-9316-4E2E69357ECAQ47345032-088ACBC8-F6E1-44FE-8E10-59998E2420D3Q47439297-402E15B6-129A-4E43-825D-8F3378A62CA5Q47818563-D1BD1E8F-6B22-4ED0-B554-81B536866DC5Q48032022-DDBED73A-38C8-4925-9123-DBFB0DC4C759Q48147276-E135323B-2D08-4A32-8720-BF6D9DC36761Q48167124-978CB45A-E03D-4E64-BE96-72A703A8D96CQ50057726-C5759051-195C-4562-B4B1-8C2C795423BFQ52655175-C08F3203-822E-4E8C-AC41-31FE18342251Q53396593-6A24004D-8538-4546-B0F5-058F356F1C8DQ54315033-E3380D4C-7CDE-43C4-9E0C-3DC4242734C5Q57243478-E44C9ED2-90C4-4C4A-A9F4-F6290D2D9C0FQ57287566-26C508D5-335A-4551-BFE3-7168C4A04849Q57384620-214FDC17-86E4-413C-B877-91AEF5B236F3Q57475963-E1B8B993-85C4-4DC3-BD1A-75FE21B4AC5DQ58577420-3AA8FF5D-037F-4FDE-B07D-FD14A93A0562Q60300790-12DF0E0C-AFD7-4D2F-B71E-57E13B640C74Q60606962-9B840663-87F4-4438-8987-F69FED73ACD2Q60796498-59749D5C-F9FA-499D-8760-D6FBF00AAF1AQ62963901-A9624152-6941-4D03-B823-8F99AAD67638
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Irmela Jeremias
@ast
Irmela Jeremias
@en
Irmela Jeremias
@es
Irmela Jeremias
@nl
type
label
Irmela Jeremias
@ast
Irmela Jeremias
@en
Irmela Jeremias
@es
Irmela Jeremias
@nl
prefLabel
Irmela Jeremias
@ast
Irmela Jeremias
@en
Irmela Jeremias
@es
Irmela Jeremias
@nl
P106
P31
P496
0000-0003-1773-7677